Avidity Biosciences Plans Major Stock Offering
Avidity Biosciences, Inc. (NASDAQ: RNA), a pioneering biopharmaceutical company known for its innovative RNA therapeutics, has disclosed its intention to conduct a public offering of common stock valued at approximately $500 million. This strategic move aims to support the company’s expanding portfolio of RNA-based treatments, specifically Antibody Oligonucleotide Conjugates (AOCs™), a revolutionary approach in the realm of medicine.
Details of the Proposed Offering
The company plans to offer and sell common stock shares, and additionally, it has provided underwriters with an option to purchase an extra $75 million in shares for a period of 30 days after the initial offering. All shares issued in this offering will come directly from Avidity, reaffirming its commitment to enhancing its capital for future initiatives. While the market conditions may influence the timing and final size of the offering, Avidity is prepared to move forward with this ambitious financial strategy.
Intended Use for Proceeds
The anticipated funds from the offering will be utilized to further bolster Avidity’s development initiatives. Key areas of focus include:
- Advancing three critical late-stage clinical programs.
- Creating sufficient commercial inventory for expected product launches.
- Expanding the company’s commercial infrastructure.
- Propelling research and development efforts associated with the AOC platform.
- Covering general corporate expenses and working capital needs.
Leadership in the Offering
Renowned financial institutions are involved in this offering as joint bookrunning managers, including Leerink Partners, J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities. Their expertise will guide Avidity in navigating the complexities of this public offering, aimed at drawing the interest of potential investors in the biopharmaceutical sector.
About Avidity Biosciences
Avidity's mission revolves around delivering transformative RNA therapeutics that can significantly improve patient outcomes. Utilizing its groundbreaking AOC technology, Avidity combines the targeting ability of monoclonal antibodies with the therapeutic potential of RNA oligonucleotides. This innovative approach enables the treatment of previously difficult-to-address diseases.
Currently, Avidity is engaged in clinical programs targeting rare muscle conditions such as myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Furthermore, the organization is actively pursuing development initiatives in precision cardiology, reinforcing its commitment to addressing significant unmet medical needs through AOCs.
The company continues to lead in clinical development, showcasing the first successful targeted RNA delivery into muscle tissue, thereby setting new standards in the field of RNA therapies, with a steadily expanding pipeline that encompasses cardiology and immunology applications.
Investor and Media Contacts
For those seeking further details about the offering, Avidity has provided clear avenues for inquiry:
- Investor Contact: Kat Lange, (619) 837-5014.
- Media Contact: Kristina Coppola, (619) 837-5016.
This offering represents a significant milestone in Avidity's journey to reshape the landscape of RNA therapeutics, paving the way for advancements that could profoundly impact the lives of patients facing severe and rare diseases.
Frequently Asked Questions
What is Avidity Biosciences known for?
Avidity Biosciences specializes in RNA therapeutics, incorporating Antibody Oligonucleotide Conjugates to treat previously hard-to-address diseases.
How much is Avidity planning to raise in this offering?
Avidity intends to offer approximately $500 million in common stock, with an additional option for underwriters to purchase $75 million worth of shares.
What will the proceeds from the offering be used for?
The funds will advance clinical programs, enhance commercial inventory, expand infrastructure, and support ongoing R&D efforts.
Who are the joint managers for the offering?
Leading financial institutions including Leerink Partners, J.P. Morgan, and Wells Fargo Securities are managing the offering.
Where is Avidity Biosciences headquartered?
Avidity is headquartered in San Diego, California, where it conducts its innovative research and development activities.
